Oct 31 (Reuters) - U.S. prosecutors are focusing on Valeant Pharmaceuticals International Inc’s former chief executive and chief financial officer as they build a fraud case against the drugmaker, Bloomberg reported.
The case against Valeant could yield charges within weeks, the report said, citing people familiar with the matter. (bloom.bg/2fnXLYp)
Valeant’s U.S.-listed shares tumbled 5.5 percent to $19.23. The company could not be immediately reached for comment.
Earlier this year Laval, Quebec-based Valeant replaced its long-time CEO Michael Pearson with Perrigo Co Plc’s CEO, Joseph Papa. (Reporting by Ankur Banerjee in Bengaluru; Editing by Savio D’Souza)